Amgen

We are all different, yet we have this in common: our mission to serve patients. This sense of shared purpose is key to our becoming one of the world’s leading biotechnology companies. It guides us as we continue to launch new medicines and reach millions of patients worldwide.

We live the mission.

We win together.

We thrive on continual challenge.

Our team of 27,000+ scientists and professionals worldwide bring distinct perspectives and experiences to all we do. We leverage our global talent to achieve together—to research, manufacture and deliver ever-better products and greater depth to our mission.

At Amgen, there is a strong correlation between our high level of diversity and performance. Because addressing issues with a wider range of perspectives and approaches leads to more creative problem-solving. Together, we’re transforming the promise of science and biotechnology into therapies that have the power to restore health.

Connect with us to explore how you can Win, Live, and Thrive at Amgen.

AWARDS

Corporate Headquarters
One Amgen Center Drive
Thousand Oaks, CA 91320

Tel: 805-447-1000

Visit website

Email Us

LIVE. WIN. THRIVE.

We know an idea—any idea—can blossom into a lifesaving treatment. That’s why we dare to ask the questions most people won’t. Join us in pushing biotechnology.

Join Us

Employee Testimonials

“Amgen fosters a culture of innovation, with a science-based risk approach, centered in the benefit of our patients and powered by the diversity of our staff.”

Jorge D.
Porcess Scientific Director
Juncos, PR
“Cultivate your curiosity and continue to learn at Amgen — grow daily and explore career opportunities that align with your competencies and motivation”

Fernando F.
Executive Director Plant Manager
Rhode Island, US
“Working at Amgen, as Specialist Quality Control gives me the opportunity to work with Amgen products in benefit of the patients. Using my knowledge in science and share my diversity with my peers, is the best experience I have as part of the Amgen family.”

Niria R.
Specialist Quality Control
Juncos, PR

Diversity and Inclusion
Benefits
Community Investment
Awards and Accolades

Serving patients across the globe requires a global team. We continue building a diverse workforce that reflects the needs of those they serve, bringing with them innovative ideas that can push biotechnology forward.

Learn More

We offer more than benefits. Our Total Rewards Program secures the long-term financial, physical and overall well-being of you and your family. Among leading biotechnology and pharmaceutical leaders, we stand among the very best.

Learn More

Through Amgen Volunteers, you can dedicate eight hours to participating organizations of your choice. This along with matching employee donations to charities and our diverse corporate giving initiatives are just some ways you can make meaningful contributions as a global citizen

Learn More

Amgen is proud of the achievements we have realized as a mission-driven team—particularly the accolades we have earned as an employer. You can find our teams named in respected lists including Forbes, Fast Company and more.

Learn More

NEWS

Pictured: A suited arm pointing a dart at a bullse

Deals

Psychedelics, Solid Tumors Will Be Key Focuses for Investors in 2024

After oncology and neuroscience headlined biopharma investment in 2023, experts anticipate increased interest in the autoimmune and obesity spaces this year.

March 5, 2024

5 min read

Heather McKenzie

Amgen sign at its headquarters in Thousand Oaks, California, USA.

Drug Development

Amgen’s Weight-Loss Drug Candidate Shows Promise in Early Data

Phase I results published Monday suggest Amgen’s investigational weight-loss drug MariTide produces longer-lasting effects than GLP-1s currently on the market.

February 5, 2024

1 min read

Kate Goodwin

Pictured: Amgen's office in Tampa, Florida

Policy

Amgen’s Osteoporosis Drug Gets FDA Boxed Warning for Hypocalcemia Risk

The regulator concluded that Prolia (denosumab) increases the risk of severe hypocalcemia, which may result in hospitalization and could trigger life-threatening events or even lead to death.

January 22, 2024

2 min read

Tristan Manalac

Pictured: FDA sign at its office in Washington, DC/iStock, JHVEPhoto

Policy

FDA Action Alert: Calliditas, Ionis/AstraZeneca, Amgen and More

The year may be coming to a close, but there’s no holiday break for the FDA, which will release five regulatory verdicts over the next two weeks.

December 13, 2023

4 min read

Tristan Manalac

Pictured: Boehringer Ingelheim's office in California

Business

Boehringer Ingelheim Targets Stroma-Rich Cancers in Potential $509M AI Deal

The pharma giant is paying $9 million upfront to Phenomic AI to develop targets for stroma-rich cancers, some of the hardest cancers to treat, utilizing its single-cell RNA computing platform.

November 29, 2023

2 min read

Kate Goodwin

Pictured: A red, blue and purple racecar zip aroun

Drug Development

Mirati, Amgen, Lilly and More Race to the Front Line in KRAS-Mutated NSCLC

While Amgen and Mirati are widely viewed as frontrunners to win the first front line approval, analysts—and competitors—say the field is still wide open.

November 21, 2023

6 min read

Mollie Barnes

Pictured: Entrance to the U.S. Department of Healt

Policy

HHS Considers Removing J&J’s Stelara from Medicare Drug Price Negotiations

The Department of Health and Human Services in a court filing last week said that the blockbuster treatment could be “deselected” from the drug price negotiation list, given the recent approval of Amgen’s Stelara biosimilar.

November 7, 2023

2 min read

Tristan Manalac

FDA

Amgen Contests J&J’s Stelara with FDA Approval for Interchangeable Biosimilar

Ahead of the Inflation Reduction Act’s drug price negotiations, the regulator has approved Amgen’s biosimilar challenge to Johnson & Johnson’s Stelara—with an interchangeable designation to boot.

November 2, 2023

3 min read

Tristan Manalac

Pictured: Amgen's office in Massachusetts/iStock,

Business

Amgen Axes Prostate Cancer Drug, Takes $650M Write-Down as Q3 Profit Drops

In its third-quarter results Tuesday, Amgen announced a $650 million write-down after discontinuing AMG 340, a prostate cancer candidate acquired in the $900 million buy of Tenobio in 2021.

October 31, 2023

2 min read

Kate Goodwin

JOBS